As Itolizumab has been in use in India since 2013 and given the number of clinical trials ongoing during the coronavirus disease 2019 (COVID-19) pandemic, it may be feasible to examine antiviral humoral responses during vaccination as well as primary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in patients that had been receiving CD6 monoclonal blocking antibody therapies (12, 13, 67, –, 69). Here, CD6 is linked to COVID-19.